Skip to content

Retrospective Study on Myopia Management with Moderate-to-High Astigmatism Using Diffusion Optics Technology

Retrospective Study on Myopia Management with Moderate-to-High Astigmatism Using Diffusion Optics Technology

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500107976
Enrollment
Unknown
Registered
2025-08-21
Start date
2025-09-01
Completion date
Unknown
Last updated
2025-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia with Moderate-to-High Astigmatism

Interventions

Diffusion Optics Technology Group:None
Stellest Group:None

Sponsors

Shanghai General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Chinese adolescents and children aged 6 to 15 years old at the time of first wearing target lenses; 2. Diagnosed with myopia combined with astigmatism, dilated spherical equivalent magoscopia (SER) <= -1.00 D, astigmatism within the range of -1.00 D to -4.00 D (or absolute value 1.00 D to 4.00 D) (cylinder); 3. The best corrected visual acuity in both eyes is 0.8 or above; 4. During the target time period (2023.07.01 - 2025.06.30), the first prescription and successful fitting of wear-controlled glasses or Xingqu control defocus glasses as the main myopia control intervention, and the lens luminosity should cover the full correction prescription (including spherical lenses and all astigmatism); 5. Have glasses records and key follow-up visits, complete baseline, 6 months, 12 months, 18 months, and 24 months visit data, including at least ciliary muscle palsy or subpupillary refraction, and axial length measurement data.

Exclusion criteria

Exclusion criteria: 1. Allergy or intolerance to cycloplegic drugs; 2. Other eye diseases that may significantly affect vision, refractive development, or interfere with the effect of lenses (such as: strabismus>15PD, moderate to severe amblyopia (BCVA<0.6), keratoconus, active ocular surface diseases, cataracts, glaucoma, known retinopathy, optic nerve disease, etc.); 3. Use at the same time during the observation period (pre-baseline or post-baseline follow-up period) or switch to other myopia control interventions (such as: low-concentration atropine eye drops, orthokeratology lenses, OK lenses, multifocal soft contact lenses, other brands/types of defocus frame lenses, etc.) during the study period; 4. History of ocular surgery that affects refractive status (including strabismus correction); 5. Missing baseline data or key follow-up data (especially dilated refraction and AL) or incomplete and unreliable records; 6. Poor wearing compliance (according to medical records, the doctor clearly judges or the patient reports that he rarely wears target glasses); 7. Not wearing this type of lens for the first time (i.e. wearing lenses of the same brand before).

Design outcomes

Primary

MeasureTime frame
Change in cycloplegic spherical equivalent refraction (SER) from baseline to Month 24;

Secondary

MeasureTime frame
Change in cycloplegic SER from baseline to Month 12;Change in non-cycloplegic cylinder power from baseline to Month 24;Change in non-cycloplegic cylinder power from baseline to Month 12;Change in axial length (AL) from baseline to Month 24;Change in axial length (AL) from baseline to Month 12;

Countries

China

Contacts

Public ContactTianwei Qian

Shanghai General Hospital

qtw6180@126.com+86 152 0195 5168

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026